Smoking associated with major urologic cancer surgical complications
the ONA take:
According to a study presented at the 2015 annual meeting of the American Urological Association in New Orleans, Louisiana, researchers have found that smokers and previous smokers are more likely to experience complications during and after major urologic cancer surgery and that quitting smoking for even just 1 year significantly improves surgical outcomes.
For the study, researchers identified 9,014 patients who underwent surgery for bladder, kidney, or prostate cancer from the American College of Surgeons National Surgical Quality Improvement Program database and identified.
Results showed current smokers had an increased risk for pulmonary and kidney complications and longer duration of hospitalization after prostate cancer surgery. In addition, patients with bladder cancer who currently smoked had an increased risk for requiring further surgery and former smokers had an increased risk for readmission.
Patients with prostate cancer who had not smoked for at least 1 year prior to surgery had a similar risk for surgical complications as non-smokers and had a significantly lower risk than current smokers.
The findings suggest that health care providers should motivate patients to quit smoking prior to undergoing major surgery in order to reduce the risk for complications.
Smokers and previous smokers are more likely to experience complications during and after major urologic cancer surgery.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|